CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 289 enrolled
Drug / intervention
Paliperidonedrug
Likely dose
Paliperidone 6 milligramfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00784238
NCT00784238Phase 4Completed
CompareCT.gov

An Open-label, Prospective, Non-Comparative Study to Evaluate Subjective Well-Being and Responses in Patients With Schizophrenia Who Had Switched to Paliperidone Extended-Release Tablets

Janssen Korea, Ltd., Korea·interventional·Posted Nov 3, 2008·Updated Mar 27, 2014

In Brief

A Phase 4 clinical trial evaluating Paliperidone for Schizophrenia. Completed, enrolled 289 participants across 11 sites.

Detailed Summary

The purpose of this study is to evaluate improvement and efficacy of paliperidone extended-release for subjective well-being and drug attitudes of participants, when switching from oral antipsychotics in participants with schizophrenia (psychiatric disorder with symptoms of emotional instability, detachment from reality, often with delusions and hallucinations, and withdrawal into the self).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSchizophrenia
CountriesSouth Korea
Collaborators--

Timeline

Phase 4CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedNov 3, 2008
Enrollment StartApr 1, 2008
Primary CompletionDec 1, 2010
Study CompletionJan 1, 2011
TodayJul 2, 2026
Enrollment to primary: 2.7 yearsPosted 17.7 years ago

Interventions

Paliperidonedrug

Paliperidone ER oral tablet will be administered once daily at a starting dose of 6 milligram (mg) for 24 weeks, wherein dose range will be 3 to 12 mg per day.